Diffusion-weighted MRI in metastatic gastrointestinal tumors (GIST): A pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT
Details
Serval ID
serval:BIB_5B51B12101C4
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
Diffusion-weighted MRI in metastatic gastrointestinal tumors (GIST): A pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT
Title of the conference
Swiss Radiological Congress 2010, Schweizerische Gesellschaft für Radiologie, Schweizerische Gesellschaft für Nuklearmedizin, Schweizerische Vereinigung der Fachleute für medizinisch technische Radiologie
Address
Lugano, Switzerland, June 3-5, 2010
ISBN
1424-4985
Publication state
Published
Issued date
2010
Volume
10
Series
Swiss Medical Forum = Forum Médical Suisse
Pages
12
Language
english
Abstract
Purpose: To evaluate the clinical potential of diffusion-weighted MR
imaging with apparent diffusion coefficient (ADC) mapping for the
assessment of gastrointestinal stromal tumor (GIST) response to
targeted therapy in comparison with 18F-FDG PET/CT.
Methods and materials: Five patients (3W/2M, aged 56 ± 13 y) with
metastatic GIST underwent both a 18F-FDG PET/CT (Discovery LS,
GE Healthcare) and a MRI (VIBE T1 Gd, DWI [b = 50,300,600] and
ADC mapping) before and after change in therapy. Exams were first
analyzed blindly, then PET/CT images were coregistered to T1 Gd MR
images for lesion detection. SUVmax and ADC were measured for the
six largest lesions on MRI. The relationship between SUVmax and ADC
was analyzed using Spearman's correlation.
Results: Altogether, 24 lesions (15 hepatic and 9 non-hepatic) were
analyzed on both modalities. Three PET/CT lesions (12.5%) were
initially not considered on ADC and 4 lesions on the second PET/CT
were excluded because of hepatic vascular activity spillover. SUVmax
decreased from 7.2 ± 7.7 g/mL to 5.9 ± 5.9 g/mL (P = 0.53) and ADC
increased from 1.2x10-3 mm2/s ± 0.4 to 1.4x10-3 mm2/s ± 0.4 (P = 0.07). There was a significant association between SUVmax decrease and
ADC increase (rho= -0.64, P = 0.004).
Conclusion: Changes in ADC from diffusion-weighted MRI reflect
response of 18F-FDG-avid GIST to therapy. The exact diagnostic value
of DWI needs to be investigated further, as well as the effect of lesion
size and time under therapy before imaging. Furthermore, the proven
association between SUVmax and ADC may be useful for the
assessment of treatment response in 18F-FDG non-avid GIST.
imaging with apparent diffusion coefficient (ADC) mapping for the
assessment of gastrointestinal stromal tumor (GIST) response to
targeted therapy in comparison with 18F-FDG PET/CT.
Methods and materials: Five patients (3W/2M, aged 56 ± 13 y) with
metastatic GIST underwent both a 18F-FDG PET/CT (Discovery LS,
GE Healthcare) and a MRI (VIBE T1 Gd, DWI [b = 50,300,600] and
ADC mapping) before and after change in therapy. Exams were first
analyzed blindly, then PET/CT images were coregistered to T1 Gd MR
images for lesion detection. SUVmax and ADC were measured for the
six largest lesions on MRI. The relationship between SUVmax and ADC
was analyzed using Spearman's correlation.
Results: Altogether, 24 lesions (15 hepatic and 9 non-hepatic) were
analyzed on both modalities. Three PET/CT lesions (12.5%) were
initially not considered on ADC and 4 lesions on the second PET/CT
were excluded because of hepatic vascular activity spillover. SUVmax
decreased from 7.2 ± 7.7 g/mL to 5.9 ± 5.9 g/mL (P = 0.53) and ADC
increased from 1.2x10-3 mm2/s ± 0.4 to 1.4x10-3 mm2/s ± 0.4 (P = 0.07). There was a significant association between SUVmax decrease and
ADC increase (rho= -0.64, P = 0.004).
Conclusion: Changes in ADC from diffusion-weighted MRI reflect
response of 18F-FDG-avid GIST to therapy. The exact diagnostic value
of DWI needs to be investigated further, as well as the effect of lesion
size and time under therapy before imaging. Furthermore, the proven
association between SUVmax and ADC may be useful for the
assessment of treatment response in 18F-FDG non-avid GIST.
Publisher's website
Create date
01/07/2010 10:41
Last modification date
20/08/2019 15:14
Usage data
